| Literature DB >> 34074315 |
Eugen Mengel1, Bruno Bembi2, Mireia Del Toro3, Federica Deodato4, Matthias Gautschi5, Stephanie Grunewald6, Sabine Grønborg7, Bénédicte Héron8, Esther M Maier9, Agathe Roubertie10, Saikat Santra11, Anna Tylki-Szymanska12, Simon Day13, Tara Symonds14, Stacie Hudgens15, Marc C Patterson16, Christina Guldberg17, Linda Ingemann17, Nikolaj H T Petersen17, Thomas Kirkegaard17, Christine Í Dali17.
Abstract
Entities:
Year: 2021 PMID: 34074315 PMCID: PMC8168003 DOI: 10.1186/s13023-021-01855-9
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
.
Abstract background, page 1: cholestane-3 | cholestane-3β,5α,6β-triol |
Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001), HSP70 (p < 0.0001) and skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411). | Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001) and HSP70 (p < 0.0001), and significantly higher levels of skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were also significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and were correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411). |
2014–005,194-37 | 2014-005193-37 |
that affect gross motor skills, swallowing ability cogni- | that affect gross motor skills, swallowing ability and cogni- |
tion still had an end-of-trial visit and provided data for | tion still had an end of study visit and provided data for |
by referring clinicians as current medical conditions, was | by referring clinicians as current medical conditions, were |
(Fig. 3b). | (Fig. 3c). |
an end-of-trial visit and is included in efficacy assessments | an end of study visit and is included in efficacy assessments |
Total number of different alleles | Total number of distinct alleles |
Change in disease biomarkers over the 6–14-month observation period compared with those of healthy individuals | Disease biomarkers over the 6–14-month observation period and those of healthy individuals |
(Table 6). | (Table 7). |
Serious adverse events [indented] | This is incorrectly indented, please align to the left. |
| Table 6 | Table 7 |
| Table 7 | Table 6 |
(Table 7). | (Table 6.) |
MEAN 5-domain NPCCSS score (±SD) | Mean 5-domain NPCCSS score (±SD) |
date and to confirm the patients and clinicians view on clinical meaningful changes on the 5-domain NPCCSS | date and to confirm the patients’ and clinicians’ views on clinically meaningful changes on the 5-domain NPCCSS |
tane burden with NPC disease severity [22]. However, | tane triol burden with NPC disease severity [22]. However, |
this was likely owing to the limited viability of PBMCs | this was likely due to the limited viability of PBMCs |
uting to the 5-domain NPCCSS were locally independent | uting to the 5-domain NPCCSS was locally independent |
Incorrect formatting of citation (15) | Delete |
Incorrect formatting of abbreviation and citation (ICC2,13) | (ICC) [2,13] |
MCID: Minimal clinically important difference; | Delete |